Co-Diagnostics (CODX) investor relations material

Executive summary

• Special Meeting scheduled for December 5, 2025, to vote on a reverse stock split amendment.

• Proposal seeks authority for a reverse stock split at a ratio between 1-for-2 and 1-for-30, with the final ratio to be set by the Board within twelve months.

• Main objective is to regain compliance with Nasdaq’s $1.00 minimum bid price requirement and avoid delisting.

• Board unanimously recommends voting in favor of the proposal.

• If approved, the Board may implement or abandon the split at its discretion within the authorized timeframe.

Voting matters and shareholder proposals

• Only shareholders of record as of October 29, 2025, are eligible to vote; each share equals one vote.

• Proposal requires a majority of votes cast for approval; abstentions and broker non-votes do not count as votes cast.

• Shareholders can vote by mail, phone, internet, or in person; proxies can be revoked before the meeting.

• No dissenters’ rights are available for this proposal.

• Shareholder proposals for the 2026 meeting must be submitted by December 15, 2025, to be considered for inclusion.

Board of directors and corporate governance

• Board retains discretion to set the reverse split ratio and timing or to abandon the split.

• Board and executive officers as a group own 5.4% of outstanding shares; no individual owns more than 1.4%.

• Shareholders can communicate directly with the Board via confidential email.